AzTrials
AzTrials

Liver Transplant; ComplicationsNCT05065125

Clinical Usefulness of Digital Single-operator Cholangioscopy(SpyGlass™) for Post-liver Transplant Anastomotic Stricture

An observational study of Liver Transplant; Complications and Biliary Duct Obstruction, run by Seoul National University Hospital at 1 site in South Korea.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Liver transplantation (LT) is an essential treatment for end-stage liver disease. Although clinical outcomes of LT recipients have markedly improved, anastomotic biliary strictures (ABS) are still occurred in 10-40% of post-LT patients. Read more about this study

Who is it for?
Ages 19 years and older
What is being tested?
digital single-operator cholangioscopy
Type of treatment
Medical device
How many people
40 participants
Where
1 siteSouth Korea
Study dates
5 Oct 2021to Dec 2024
How long will I take part?
1 Month
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 19 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: LDLT patients with anastomotic biliary stricture

Who may be able to join

  • Age 19 or older
  • Patients who treated with LDLT (Duct-to-duct anastomosis)
  • Patients with confirmed anastomosis site biliary stricture using cross-sectional imaging study (CT, MRI/MRCP).

Who cannot join

  • Patients with age 18 or under
  • Pregnant woman
  • Patients unable to endoscopic (transpapillary) approach due to prior surgical history
  • Patients who did not provide informed consent to participation in the study

Trial locations and contacts

1 site in 1 country.

South Korea1 site, 1 recruiting
  • Seoul National University Hospital

    Seoul, 03080

    Sang Hyub Lee, MD, PhD, 82-2072-2228, gidoctor@snuh.org

    Recruiting

Other trials in South Korea

About this study

Official title: Clinical Usefulness of Digital Single-operator Cholangioscopy (SpyGlass™) for Post-liver Transplant Anastomotic Stricture

Liver transplantation (LT) is an essential treatment for end-stage liver disease. Although clinical outcomes of LT recipients have markedly improved, anastomotic biliary strictures (ABS) are still occurred in 10-40% of post-LT patients.

In the Korea, living donor LT (LDLT) is the more common than deceased donor LT (DDLT). When LDLT is performed, the right lobe graft is usually used, and the right anterior and posterior segmental bile ducts (RASD/RPSD) of the graft are reconstructed by the duct-to-duct anastomosis method to the common hepatic duct of the recipient.

Read more

When ABS occurs in LDLT recipients, the stricture site is often very tight and twisted. So, conventional endoscopic procedure is challenging and success rate of ERCP for ABS is still unsatisfactory (about 60%). Furthermore, approach to the RPSD is more intricate than that to RASD because the duct opening is located deeper in a posterior aspect. Therefore, despite being able to benefit the patient, bilateral drainage (both RASD and RPSD) is considered to be more difficult and unilateral drainage of RASD is mainly performed.

In 2015, high-resolution cholangioscopy (SpyGlass™) was introduced. The system enables direct visualization of the bile and pancreatic ducts strictures. The 3rd Generation SpyScope DS II Access \& Delivery Catheter introduced in 2018, features increased resolution and adjusted lighting to provide physicians with an even better view of the biliary and pancreatic ducts. To date, only several retrospective studies have evaluated the efficacy of SpyGlass for guidewire placement across the ABS and to the best of our knowledge only one prospective study is ongoing (ClinicalTrials.gov NCT #03205072). In that study ABS in both LDLT and DDLT patients are enrolled. Private communications with the Sponsor of this study, however, have reported that only approximately 10% of the cases are LDLT cases. In addition, there is no reported paper about the usefulness of Spyglass for bilateral drainage and its clinical benefit in post LT ABS.

If successful bilateral drainage is performed by using Spyglass, it may be more helpful for patients than unilateral drainage as it allows sufficient drainage of the transplanted liver. With this prospective study, we intends to investigate the efficacy of Spyglass for bilateral drainage of ABS in LDLT patients and improve drainage success rate. This results can be used as clinical basis for further studies such as randomized controlled trial.

Being tested
digital single-operator cholangioscopy

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • digital single-operator cholangioscopyDevice

    1. Duodenoscope passes through esophagus and stomach to the papilla of Vater
    2. SpyScope DS Catheter passes through the duodenoscope and into common bile duct
    3. After direct visualization of anastomosis site stricture, guidewire is passed through SpyScope DS Catheter above the stricture site.
Study groups in NCT05065125
Study groupRoleWhat they receive
LDLT cohortLiving-donor liver transplatation (LDLT) patients with anastomotic biliary stricture
Receives: Device: digital single-operator cholangioscopy

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Rate of Technical success

    ① Successful guidewire placement across the stricture site or

    ② Successful subsequent treatment (advancement of dilatation balloon and/or placement of biliary endoprosthesis across the stricture when intended).

    Measured: During endoscopic treatment (ERCP with SpyGlass)

Secondary outcomes (3)
  1. Rate of Clinical success

    Rate of improvement of abdominal pain, obstructive jaundice or infection at one month after treatment

    Measured: after a month of ERCP procedure

  2. Rate of Complication rate

    post-procedural cholangitis, pancreatitis, bleeding, or perforation

    Measured: after a month of ERCP procedure

  3. Rate of Recurrence rate

    re-intervention within 1 month

    Measured: after a month of ERCP procedure

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted1 Oct 2021
  2. Study start5 Oct 2021
  3. Primary completionSep 2024 (estimated)
  4. Study completionDec 2024 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
40 participants (estimated)
Target duration
1 Month
IDs, dates and publications
ClinicalTrials.gov ID
NCT05065125
Sponsor's protocol ID
H-2105-134-1219
Status last verified
Oct 2021
First submitted
22 Sep 2021
Last updated
21 Oct 2021
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No

Publications

  • Cho IR, Lee SH, Kang J, Kim J, Lee TS, Lee MH, Lee MW, Choi JH, Paik WH, Ryu JK, Kim YT, Hong SK, Choi Y, Yi NJ, Lee KW, Suh KS. Digital single-operator cholangioscopy for difficult anastomotic biliary strictures in living donor liver transplant recipients after failure of standard ERCP: SPYPASS-2 study (with videos). Gastrointest Endosc. 2025 May;101(5):979-987.e3. doi: 10.1016/j.gie.2024.11.017. Epub 2024 Nov 16.

    PubMed 39557203

Questions about this trial

What is this clinical trial studying?

An observational study of Liver Transplant; Complications and Biliary Duct Obstruction, run by Seoul National University Hospital at 1 site in South Korea.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 21 Oct 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in South Korea. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Rate of Technical success (time frame: During endoscopic treatment (ERCP with SpyGlass)). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05065125, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Oct 2021; AzTrials last refreshed its copy on 6 Nov 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in